Risk Factors Update Summary
- Added the risk of not having a marketing and sales force, potentially impacting sales effectiveness. This could lead to significant additional losses.
- Disclosed the commencement of Phase 2 clinical development of rosnilimab and ANB032, with collaboration revenue increasing from $10 million to $17 million.
- Highlighted the importance of attracting and retaining skilled employees for success, with net loss increasing from $128 million to $163 million.
- Mentioned the termination of the anti-LAG-3 antagonist antibody development program with GSK, ending milestone and royalty payments.
- Noted the potential impact of geopolitical instability due to the ongoing military conflict in Ukraine on financial institutions and stock price volatility.
- Discussed the risks associated with the failure to comply with privacy and data security laws, potentially leading to significant fines and penalties.
- Added the risk of adverse effects on operations and financial performance due to the failure of financial institutions where cash is held.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1370053&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.